Kiromic BioPharma, Inc. (KRBP)
| Market Cap | 67.61M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -16.28M |
| Shares Out | 7.33M |
| EPS (ttm) | -2.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 25 |
| Last Price | $8.75 |
| Previous Close | $9.23 |
| Change ($) | -0.48 |
| Change (%) | -5.20% |
| Day's Open | 9.50 |
| Day's Range | 8.75 - 9.55 |
| Day's Volume | 17,387 |
| 52-Week Range | 8.11 - 11.50 |
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platfo...
HOUSTON--(BUSINESS WIRE)--Kiromic Biopharma, Inc. (Nasdaq: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and proprietary neural network platform with a t...
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma (“the Company”) (NASDAQ: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network pla...
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma (“the Company”) (NASDAQ: KRBP), a pre-clinical stage biotechnology company using its proprietary DIAMOND® artificial intelligence (“A.I.”) platform ...
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (the “Company”), a target discovery and gene-editing company utilizing artificial intelligence and a proprietary neural network platform with ...
About KRBP
Kiromic BioPharma, a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. Its product portfolio include ALEXIS AIDT-1, an allogenic CAR cell product candidate targeting AIDT-1; ALEXIS AIDT-2 EOC, an allogenic CAR cell product candidate targeting AIDT-2; ALEXIS AIDT-2 MPM (malignant pleural mesothelioma), an allogenic CAR/NKT-Like cell product candidate targeting AIDT-2; and PD-1-AR, a check point inhibitor for solid tumors, as well as oral healthcare p... [Read more...]
| Industry Biotechnology | IPO Date Oct 16, 2020 |
| CEO Dr. Maurizio Chiriva Internati Ph.D. | Employees 11 |
| Stock Exchange NASDAQ | Ticker Symbol KRBP |